Some imported branded drugs will soon face tariffs as high as 100%, the Trump administration announced Thursday. But not every drugmaker will pay — many are getting exemptions tied to drug pricing deals and domestic production plans.
New Tariffs Target Branded Pharmaceuticals Without Pricing Deals
The Trump administration unveiled a fresh round of tariffs aimed squarely at branded pharmaceutical imports. The levies, which could reach 100% on certain patented drugs and their active ingredients, are designed to protect and promote domestic drug manufacturing in the US.
"We need to make sure that our drug supply is protected, secure and domestic," a senior administration official told reporters on Thursday, speaking on condition of anonymity.
The tariffs will hit companies that haven't agreed to lower their drug prices under arrangements with the government. Drugmakers who have signed pricing deals or are actively negotiating with the Department of Health and Human Services (HHS), and who are building manufacturing capacity in the US, stand to avoid these levies.
That exemption comes with deadlines: new domestic production facilities must be up and running by January 2029 to qualify. The administration also set a transition tariff for companies planning to onshore production — a 20% levy now that escalates to 100% after four years.
Timelines and Tariff Rates Vary by Company Size and Geography
Larger pharmaceutical firms face a 120-day window before the full 100% tariff kicks in. Smaller players, which often rely on contract manufacturers, have a bit longer — 180 days.
But the tariff landscape isn’t uniform worldwide. Countries with robust trade deals with the US, like the European Union, Japan, South Korea, and Switzerland, will face a reduced 15% tariff on pharmaceutical imports. Meanwhile, the UK is subject to a 10% tariff, partly reflecting its government’s recent decisions to raise prices it will pay for drugs.
"Those countries, the production can stay in those countries because they've made a bigger trade deal with America," the official explained.
Generic drugs, biosimilars, and their ingredients are currently exempt from tariffs, but the White House plans to reevaluate their status in a year.
Exemptions for Specialty Drugs and Urgent Health Needs
Certain specialty pharmaceutical products, including animal health treatments and therapies for rare diseases, will also be spared if they originate from countries with trade agreements or if they meet urgent public health needs.
This move tries to balance things by encouraging domestic production while avoiding disruptions to essential medical supplies.
Beyond drugs, the administration also revised tariffs on imported raw materials like steel, aluminum, and copper, along with products containing those metals. The adjustments aim to bolster supply chains tied to manufacturing and national security.
National Security and Trade Strategy Drive Tariff Decisions
The Commerce Department concluded that some pharmaceutical imports pose a national security risk to the United States, a key justification for these targeted tariffs.
These new levies mark another chapter in President Trump's aggressive trade policy. They come just over a month after the Supreme Court struck down a prior set of global tariffs imposed in 2025, which notably excluded pharmaceuticals. Now, the administration is taking a sector-specific tack.
The administration is pushing drugmakers to cut prices or move production back to the US to lessen dependence on risky foreign supply chains.
They’re also using a phased plan and exemptions to prevent sudden shocks or price hikes for consumers.
What the Pharma Industry Faces Moving Forward
Drug companies now face a tough choice: cut prices and invest in US plants, or pay steep tariffs on imports. The 100% tariffs could double the cost of some patented medicines coming from abroad, potentially reshaping global supply chains.
For many larger companies already negotiating pricing agreements and expanding domestic capacity, the new tariffs may not bite immediately. But smaller firms relying heavily on foreign contract manufacturing will likely feel the pressure sooner.
The 2029 deadline for new plants adds urgency to reshoring plans, signaling the administration’s long-term commitment to boosting domestic pharmaceutical manufacturing.
Meanwhile, the differentiated tariff rates across trade partners show the importance of trade agreements in the US's strategy. Countries with stronger deals enjoy lower drug tariffs, encouraging closer economic ties.
Industry experts are eager to see if companies speed up reshoring or just pay the tariffs as part of doing business.
Either way, this shows how trade policy and drug pricing are getting more connected in Washington.
Related Articles
The administration is mixing pressure and incentives to change where and how drugs get made in the US. We’ll see the real effects in the coming years as companies weigh whether reshoring pays off or if tariffs shake up the market.
This article was created with AI assistance.
